ABVX Rasio cepet Abivax S.A.

ABIVAX is a biotech developer in the field of immunology creating innovative therapies for Crohn's disease and ulcerative colitis. Experienced management is currently optimizing internal processes for the final stages of trials. Strict liquidity demonstrates the ability to settle debts excluding inventories, where the 6.16 metric serves as the target level. The business is completely independent of macroeconomic cycles, as the issuer's success is determined solely by regulatory approval.

The quick ratio assesses a company's ability to meet short-term obligations using only cash and accounts receivable, excluding slow-moving inventories. For ABIVAX (ABVX), with its outsourced R&D model, the current quick ratio reflects a critical resource buffer for paying external CRO and CMO services, confirming financial stability with minimal capital expenditure in proprietary facilities.